José Ramón Arribas

1. Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial
   2025/03/07 by Rosa de Miguel Buckley, María Lagarde, José Luís Blanco +14 · 1 voice · 1 citation
   Medicine · #HIV-related health complications and treatments #HIV/AIDS Research and Interventions #HIV/AIDS drug development and treatment